Breaking News

Emergent BioSolutions Announces Organizational Changes

The changes are expected to result in annualized savings of over $60 million.

Emergent BioSolutions, announced a sharpened strategic focus on its core businesses, consisting of medical countermeasures (MCM) and commercial products, including NARCAN (naloxone HCl) Nasal Spray, as well as contract development and manufacturing (CDMO) services.    “Emergent is undertaking these actions to strengthen our business, reduce costs and return to sustainable, long-term growth,” said Emergent President and CEO Robert Kramer. “Sharpening our focus on our core products and servi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters